Aβ1-17 (Aβ17)
Aβ1-17 (Aβ17) appears to be the second-most abundant cerebrospinal fluid (CSF) Aβ fragment, after Aβ40. AD patients have higher Aβ17 directly accessible from plasma than healthy controls. Although the confidence intervals are wide, these findings suggest that assessment of Aβ17 may increase the diagnostic performance of blood-based Aβ tests which might be developed into minimally invasive first-step screening tests for people with increased risk for AD.
blood draw, mild discomfort, in clinic visitsphlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)
Araclon Biotech Ltd., Zaragoza, Spain; Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain Hospital Universitari Vall d'Hebron - Institut de Recerca, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain; Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain
-
“Alpha-synuclein.” https://www.sciencedirect.com/topics/neuroscience/alpha-synuclein
-
Perez-Grijalba, V., Pesini, P., Allué, J. A., Sarasa, L., Montanes, M., Lacosta, A. M., ... & Ruiz, A. (2015). Aβ 1-17 is a major amyloid-β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease. Journal of Alzheimer's Disease, 43(1), 47-56. https://www.ncbi.nlm.nih.gov/pubmed/25061046
- Sharma, N., & Singh, A. N. (2016). Exploring biomarkers for Alzheimer’s disease. Journal of Clinical and Diagnostic Research: JCDR, 10(7), KE01. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020308/